Fulgent Genetics, Inc. (NASDAQ:FLGT) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Fulgent Genetics, Inc. (NASDAQ:FLGT) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Fulgent Genetics, Inc. (NASDAQ:FLGT) just released its latest second-quarter results and things are looking bullish. Results overall were solid, with revenues arriving 2.8% better than analyst forecasts at US$71m. Higher revenues also resulted in substantially lower statutory losses which, at US$0.29 per share, were 2.8% smaller than the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Fulgent Genetics, Inc.(纳斯达克证券代码:FLGT)发布了其最新的二季度业绩报告,看好前景。总体业绩表现良好,营业收入为7100万美元,比分析师预测高出2.8%。更高的营业收入也导致法定亏损大幅下降,每股0.29美元,比分析师预测的小2.8%。盈利是投资者们关注的重点,他们可以追踪公司的表现,查看分析师对明年的预测并观察对该公司的情绪是否发生了变化。我们收集了最近的法定预测来看看分析师是否根据这些结果改变了其盈利模型。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240805/0-06271118f8e702b212df0dfb81784e82-0-865a94bcfad749fb89766a348f7d710d.png/big)
Taking into account the latest results, the three analysts covering Fulgent Genetics provided consensus estimates of US$280.3m revenue in 2024, which would reflect a perceptible 3.6% decline over the past 12 months. Losses are predicted to fall substantially, shrinking 62% to US$2.06. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$280.2m and losses of US$2.31 per share in 2024. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a favorable reduction in losses per share in particular.
综合最新成果,涉及Fulgent Genetics的三名分析师提供2024年2,8030万美元的营收共识预测,这将反映过去12个月中逐渐下降的3.6%。预测亏损将大幅缩小,降低62%至2.06美元。但在最新的盈利数据公布之前,分析师对2024年的营收预测为2,8020万美元,每股亏损预测为2.31美元。虽然营收预测基本没有变化,但是情绪似乎得到了改善,分析师们提高了其数字,特别是在每股亏损方面做出了有利的减少。
There's been no major changes to the consensus price target of US$27.33, suggesting that reduced loss estimates are not enough to have a long-term positive impact on the stock's valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Fulgent Genetics at US$30.00 per share, while the most bearish prices it at US$25.00. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.
美元27.33元的一致价格目标没有发生重大变化,这表明减少的亏损估计还不足以对股票的估值产生长期积极的影响。检视分析师估值的范围可能会有所启示,以评估异常意见相对于平均值的差异。目前最看好的分析师认为每股Fulgent Genetics价值30.00美元,而最看淡的则将其定为25.00美元。尽管这些估值之间相差无几,但这表明分析师们对该公司的价值有一个相对明确的想法。
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Fulgent Genetics' past performance and to peers in the same industry. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 7.1% by the end of 2024. This indicates a significant reduction from annual growth of 14% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 6.8% annually for the foreseeable future. It's pretty clear that Fulgent Genetics' revenues are expected to perform substantially worse than the wider industry.
这些估值很有趣,但更重要的是在比较预测与Fulgent Genetics过去的表现以及同行业同样受分析师关注的公司表现时,描绘一些更广泛的笔触就可能非常有用了。这些估计表明,预计营收将减缓,预计至2024年底年化下降7.1%。这意味着与过去5年的年均增长14%相比,出现了明显的降低。相比之下,我们的数据表明,同一行业(受到分析师关注的)的其他公司在可预见的未来预计年均增长6.8%。很明显,Fulgent Genetics的营收预计表现将显著逊于整个行业。
The Bottom Line
最重要的事情是分析师增加了它对下一年每股亏损的估计。令人欣慰的是,营收预测未发生重大变化,业务仍有望比整个行业增长更快。共识价格目标稳定在28.50美元,最新估计不足以对价格目标产生影响。
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$27.33, with the latest estimates not enough to have an impact on their price targets.
需要重点注意的是,分析师们确认了明年每股亏损的估计值。好的一面是营收预测没有发生重大变化;虽然预测表明它们将表现得比整个行业差,但是共识的价格目标保持在27.33美元,并且最新的估值不足以对其价格目标产生影响。
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Fulgent Genetics analysts - going out to 2026, and you can see them free on our platform here.
在此基础上,请记住,我们仍然认为公司的长期轨迹对投资者更为重要。我们从多个Fulgent Genetics的分析师处得到2026年的预测,您可以在此处免费查看这些预测。
We also provide an overview of the Fulgent Genetics Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.
此外,我们介绍了Fulgent Genetics董事会和首席执行官的报酬及在公司任职时间以及内部人士是否购买该股票的概述,点击此处查看。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。